Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis

被引:143
作者
Lee, Sang Hun [1 ,2 ]
Jeong, Dongjun [3 ]
Han, Yong-Seok [1 ]
Baek, Moo Jun [4 ]
机构
[1] Soonchunhyang Univ, Seoul Hosp, Med Sci Res Inst, Seoul, South Korea
[2] Soonchunhyang Univ, Coll Med, Dept Biochem, Cheonan 330930, South Korea
[3] Soonchunhyang Univ, Coll Med, Dept Pathol, Cheonan 330930, South Korea
[4] Soonchunhyang Univ, Coll Med, Dept Surg, Cheonan 330930, South Korea
基金
新加坡国家研究基金会;
关键词
Angiogenesis inhibitors; Vascular endothelial growth factor receptors; Cell hypoxia; Tumor microenvironment; HYPOXIA-INDUCIBLE FACTORS; FACTOR GENE-EXPRESSION; ANTI-VEGF TREATMENT; FACTOR-C; INHIBITS ANGIOGENESIS; MONOCLONAL-ANTIBODY; CANCER; CELLS; METASTASIS; CYCLOOXYGENASE-2;
D O I
10.4174/astr.2015.89.1.1
中图分类号
R61 [外科手术学];
学科分类号
摘要
The shaping of new blood vessels is a significant event in cancer growth and metastasis. Therefore, the molecular system of cancer angiogenesis has garnered considerable interest in cancer research. The vascular endothelial growth factor (VEGF) and VEGF receptor pathway are recognized as the key regulators of the angiogenic process. Activation of the VEGF/VEGF-receptor pathway initiates signaling cascades that promote endothelial cell growth, migration, and differentiation. Recently, VEGF was shown to play a role in the recruitment of bone marrow-derived endothelial progenitor cells to neovascularization sites. The role of VEGF in promoting tumor angiogenesis and the occurrence of human cancers has led to the rational design and development of agents that selectively target this pathway. Moreover, these anti-VEGFNEGF receptor agents show therapeutic potential by inhibition of angiogenesis and tumor growth in preclinical models. In this review, we summarize the role of the VEGF pathway during tumor angiogenesis.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 81 条
[61]  
Muguruma Hiroaki, 2003, Nihon Naika Gakkai Zasshi, V92, P1284
[62]  
Pal S, 2001, CANCER RES, V61, P6952
[63]   Expression and regulation of the novel vascular endothelial growth factor receptor neuropilin-1 by epidermal growth factor in human pancreatic carcinoma [J].
Parikh, AA ;
Liu, WB ;
Fan, F ;
Stoeltzing, O ;
Reinmuth, N ;
Bruns, CJ ;
Bucana, CD ;
Evans, DB ;
Ellis, LM .
CANCER, 2003, 98 (04) :720-729
[64]   Snail, ZEB and bHLH factors in tumour progression: an alliance against the epithelial phenotype? [J].
Peinado, Hector ;
Olmeda, David ;
Cano, Amparo .
NATURE REVIEWS CANCER, 2007, 7 (06) :415-428
[65]  
Price DJ, 2001, CELL GROWTH DIFFER, V12, P129
[66]  
RAK J, 1995, CANCER RES, V55, P4575
[67]  
Rak J, 2002, CANCER RES, V62, P1931
[68]   Impact of insulin-like growth factor receptor-I function on angiogenesis, growth, and metastasis of colon cancer [J].
Reinmuth, N ;
Fan, F ;
Liu, WB ;
Parikh, AA ;
Stoeltzing, O ;
Jung, YD ;
Bucana, CD ;
Radinsky, R ;
Gallick, GE ;
Ellis, LM .
LABORATORY INVESTIGATION, 2002, 82 (10) :1377-1389
[69]   Loss of hepatic NF-κB activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation [J].
Sakurai, Toshiharu ;
Maeda, Shin ;
Chang, Lufen ;
Karin, Michael .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (28) :10544-10551
[70]   Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer [J].
Sandler, Alan ;
Gray, Robert ;
Perry, Michael C. ;
Brahmer, Julie ;
Schiller, Joan H. ;
Dowlati, Afshin ;
Lilenbaum, Rogerio ;
Johnson, David H. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (24) :2542-2550